ONINTZA
SAGREDO EZQUIOGA
Profesora titular de universidad
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (17)
2023
-
Disease-modifying effects of cannabidiol, β-caryophyllene and their combination in Syn1-Cre/Scn1aWT/A1783V mice, a preclinical model of Dravet syndrome
Neuropharmacology, Vol. 237
-
Retinal Tissue Shows Glial Changes in a Dravet Syndrome Knock-in Mouse Model
International Journal of Molecular Sciences, Vol. 24, Núm. 3
2022
-
Editorial: Cannabinoids as potential treatment for neurological diseases
Frontiers in Neuroscience
-
Preclinical investigation of β-caryophyllene as a therapeutic agent in an experimental murine model of Dravet syndrome
Neuropharmacology, Vol. 205
2021
-
Chapter 2: Phytocannabinoids Versus Endocannabinoids. A Modern View of the Endocannabinoid System
RSC Drug Discovery Series (Royal Society of Chemistry), pp. 10-47
-
Neuropathological Characterization of a Dravet Syndrome Knock-In Mouse Model Useful for Investigating Cannabinoid Treatments
Frontiers in Molecular Neuroscience, Vol. 13
2020
-
Possible therapeutic applications of cannabis in the neuropsychopharmacology field
European Neuropsychopharmacology, Vol. 36, pp. 217-234
2018
-
Cannabinoid signalling in the immature brain: Encephalopathies and neurodevelopmental disorders
Biochemical Pharmacology, Vol. 157, pp. 85-96
2017
-
Effects of a sativex-like combination of phytocannabinoids on disease progression in R6/2 mice, an experimental model of huntington’s disease
International Journal of Molecular Sciences, Vol. 18, Núm. 4
2016
-
A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease
Journal of Neurology, Vol. 263, Núm. 7, pp. 1390-1400
-
Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome
Pharmacology Research and Perspectives, Vol. 4, Núm. 2
2013
-
Cannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid?
British Journal of Clinical Pharmacology, Vol. 75, Núm. 2, pp. 323-333
-
Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy
Journal of Alzheimer's Disease, Vol. 35, Núm. 3, pp. 525-539
-
The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: A potential role of cyclooxygenase-2-dependent metabolism of 2-AG
Cell Death and Disease, Vol. 4, Núm. 10
2012
-
Cannabinoids: Novel medicines for the treatment of Huntington's disease
Recent Patents on CNS Drug Discovery, Vol. 7, Núm. 1, pp. 41-48
2009
-
Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity
Brain, Vol. 132, Núm. 11, pp. 3152-3164
2007
-
Cannabinoids and neuroprotection in Basal ganglia disorders
Molecular Neurobiology, Vol. 36, Núm. 1, pp. 82-91